Clinical Trial Record

Return to Clinical Trials

EUS-guided Ethanol Ablation of an Insulinoma


2014-03


2016-04


2018-04


50

Study Overview

EUS-guided Ethanol Ablation of an Insulinoma

The present study aims to evaluate the feasibility, safety and efficacy of EUS-guided ethanol ablation of an insulinoma.

As the major insulinomas are functioning islet cell tumors, surgical resection is currently first-line therapy for or treatment of insulinomas. However, the surgical resection of pancreatic neoplasm is conditional for specific patients and may be associated with substantial life-threatening complications. Several studies declared that endoscopic ultrasound (EUS)-guided lavage may offer an alternative to surgical resection of insulinomas. Nevertheless, their sample sizes were small and conclusions were built based on short-term outcomes. In addition, the amount of ethanol administrated for different types of insulinomas were inconsistent among those studies. The present study aims to evaluate the safety, feasibility and efficacy of EUS-guided ethanol ablation therapy of insulinomas. We will use cytopathology and immunohistochemistry in combination with EUS-FNA for diagnosis of insulinoma. After EUS-guided ethanol ablation therapy, the safety and efficacy will be assessed at the baseline and different time points during follow-up by physicians blinded to the treatment or control status.

  • Insulinoma
  • PROCEDURE: EUS-guided ethanol ablation
  • EUS0511

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2014-03-26  

N/A  

2014-04-22  

2014-04-22  

N/A  

2014-04-23  

2014-04-23  

N/A  

2014-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment


Allocation:
Na


Interventional Model:
Single Group


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Insulinoma

Patients with Insulinomas will received EUS-guided ethanol ablation therapy

PROCEDURE: EUS-guided ethanol ablation

  • Diagnostic evaluation for suspected insulinoma is performed by cytology or immunohistochemistry. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol under the guidance of EUS was injected into the lesion. The amount of ethano
Primary Outcome MeasuresMeasure DescriptionTime Frame
Efficacy of EUS-guided ethanol ablationVolumes of insulinomas before and after treatment, which are measured by cross-sectional imaging test (CT or MRS).1 to 12 month
Safety of EUS-guided ethanol ablationNumber of subjects with post-procedure adverse events1 to 12 month
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Technical feasibilityTechnical success was defined as ethanol is injected and lavaged into target tissue.during the procedure of treatment

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Adults: at least 18 years. 2. Patients with insulinomas which are evaluated by histopathology . 3. patients who have signed a written consent form.
    Exclusion Criteria:
    1. Patients whose condition is not suitable for the endoscopic procedure. 2. Patients who have blood coagulation dysfunction. 3. Patients who have mental disorders. 4. Patients who have mild or severe cardiorespiratory insufficiency. 5. Patients who have hypertension and could not be controlled to safe level. 6. Pregnant and lactating women. 7. Patients whose conditions are not suitable for the present study.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • STUDY_CHAIR: Shanyu Qin, MD. Ph.D., First Affiliated Hospital of Guangxi Medical University

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available